The National Directorate of Pharmacy and Drugs of the Ministry of Health of Panama has published the final report of the Evaluation Commission in charge of reviewing the proposals of companies interested in obtaining the license to manufacture cannabis medicine derivatives recommending 7 companies.
The companies and consortia that met the requirements and obtained the highest weights were first the Pan American Cannabis Consortium, This met all the requirements and obtained a perfect weight of 60 points out of a total of 60 points.
Likewise, the institution recommended the Green Med Consortium, which according to the evaluations fulfilled all the requirements and also obtained a weight of 60 points out of a total of 60 points.
Another of them was the Tilray Panama Consortium, to which the third recommendation fell, complying with all the requirements, achieving a weighting of 55 points out of a total of 60 points, followed by Farma Verde Corp who obtained a weight of 50 points out of a total of 60 points.
The fifth recommendation was granted to the company Canna Med Panamá, which also met all the requirements and obtained a weight of 50 points out of a total of 60 points. Adeiwa Pharma Consortium also achieved a weight of 50 points out of a total of 60 points.
The seventh recommendation fell to the Ecovid Consortium, complying with everything requested and achieving a weight of 50 points out of a total of 60 points.
The institution in charge of Panamanian health, explained that in accordance with the established criteria and requirements, the Commission recommended the allocation of up to 7 licenses, pursuant to article 21 of Law 242 of 2021.
The Ministry of Health highlighted that each of these groups has gone through a rigorous evaluation process. Last year the process began to select companies that complied with the established documentation and could obtain the coveted license to manufacture medical cannabis derivatives.